Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

Bone Biologics Corporation, a key player in the development of orthobiologic products specifically designed for spine fusion markets, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025. Jeffrey Frelick, the company’s President and Chief Executive Officer, will represent Bone Biologics at this significant industry event, which will provide a platform for management to engage in both in-person and virtual one-on-one meetings with institutional investors and industry professionals.

The conference will take place at the prestigious Lotte New York Palace Hotel, allowing for direct interaction and networking opportunities within the financial and healthcare communities. Registrations are open for those wishing to attend, either physically or virtually, reflecting the growing trend of hybrid engagement in investment discussions.

Bone Biologics focuses on regenerative medicine targeting bone health. The company is advancing its preclinical research based on the NELL-1 protein, which holds significant promise for enhancing bone regeneration. Their primary development initiative centers around a bone graft substitute specifically for spinal fusion procedures, while the company also possesses rights to explore applications in trauma and osteoporosis treatment.

This strategic participation at the H.C. Wainwright conference aims to elevate investor awareness about Bone Biologics’ innovative approaches to bone healing and regeneration, as well as its ongoing projects with select strategic partners. Management is expected to provide insights into the company’s vision, strategy, and development roadmaps, making this a pivotal moment for investors considering opportunities in the growing field of orthobiologics.

For further information about Bone Biologics and its offerings, interested parties can visit their official website at www.bonebiologics.com.

Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. This event presents a strategic opportunity for the company to showcase its innovative approaches in the orthobiologics market, particularly in relation to spinal fusion procedures where it is focusing on its NELL-1 protein research.

Investors should observe several key factors as the conference approaches. First, Bone Biologics is actively engaging with institutional investors and stakeholders, which could translate into potential partnerships or funding opportunities. Given the increasing demand for effective bone regeneration solutions, particularly in spinal procedures, Bone Biologics is positioning itself within a growing market. Investors may want to closely monitor announcements made during and after the conference regarding partnerships or progress in clinical trials.

Secondly, the focus on regenerative medicine is critical. Bone Biologics’ venture into developing a bone graft substitute not only targets spinal fusions but also has possible applications in trauma and osteoporosis. This diversification can mitigate risk and enhance long-term growth potential. Investors should evaluate how the company communicates its strategic advancements, including any updates on regulatory approvals or clinical milestones.

Finally, it's essential to consider the macroeconomic environment. As the healthcare sector navigates inflationary pressures and potential shifts in regulatory landscapes, Bone Biologics' ability to adapt and innovate will be paramount.

In summary, attending the conference could provide vital insights into Bone Biologics’ future direction. Investors should actively consider engaging with the company's management for in-depth discussions about its strategic vision and operational plans, which could reveal granular details about its path forward and the potential for growth in this niche market.